Myeloma bone disease: from biology findings to treatment approaches

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Jg. 133; H. 14; S. 1534
Hauptverfasser: Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Dimopoulos, Meletios A
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 04.04.2019
Schlagworte:
Bone Diseases - drug therapy
Bone Diseases - etiology
Denosumab - therapeutic use
Humans
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Osteocytes - pathology
ISSN:1528-0020, 1528-0020
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors, they participate in increased osteoclast activity, decreased osteoblast function, and immunosuppressed marrow microenvironment, which deregulate bone turnover and result in bone loss and skeletal-related events. Denosumab is a novel alternative to bisphosphonates against myeloma bone disease. Special considerations in this constantly evolving field are thoroughly discussed.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1528-0020
1528-0020
DOI:10.1182/blood-2018-11-852459